Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. furnished a Form 8-K to report that it has announced preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025. The company issued a press release on January 20, 2026 describing these preliminary results, which is included as Exhibit 99.1.
The information about results of operations and financial condition is being furnished under Item 2.02 of the Form 8-K and is not considered filed for purposes of certain liability provisions of the federal securities laws, unless specifically incorporated by reference in other filings.
908 Devices Inc. (MASS) reported Q3 2025 results. Revenue was $14.0 million, slightly below $14.5 million a year ago, while year-to-date revenue rose to $38.8 million from $33.4 million. Gross profit for the quarter was $7.4 million.
Operating expenses reflected a $10.7 million increase in the fair value of contingent consideration, driving a Q3 loss from continuing operations of $14.9 million. Year-to-date loss from continuing operations was $37.7 million.
The company completed the sale of its Desktop Portfolio to Repligen, recording a $56.1 million gain within discontinued operations. As a result, year-to-date net income attributable to common stockholders was $15.3 million.
Liquidity strengthened with cash and cash equivalents of $62.8 million and marketable securities of $49.3 million at September 30, 2025. Deferred revenue was $18.3 million. A current contingent consideration liability of $23.0 million reflects updated fair value tied to prior acquisitions.
Shares outstanding were 36,118,576 at September 30, 2025; as of November 5, 2025, they were 36,192,978.
908 Devices Inc. (MASS) furnished a press release announcing its financial results for the third quarter ended September 30, 2025. The release is attached as Exhibit 99.1 to a Form 8-K dated November 10, 2025.
The information under Item 2.02 is being furnished, not filed, under the Exchange Act. MASS’s common stock trades on The NASDAQ Global Market.
908 Devices Inc. Chief Financial Officer Joseph H. Griffith IV reported planned stock sales under a Rule 10b5-1 trading plan. The filings show sales on 10/02/2025 and 10/03/2025 totaling 5,000 shares (708 shares and 4,292 shares) at weighted-average prices near $9.04 and $9.05, respectively. After these transactions the reporting person beneficially owned 92,930 shares. The footnotes state the sales were executed under the 10b5-1 plan and disclose price ranges for the multiple transactions.
908 Devices Inc. insider transaction summary Joseph H. Griffith IV, the company’s Chief Financial Officer, reported the sale of 5,000 shares of 908 Devices Inc. (ticker: MASS) on 09/19/2025 at a weighted-average price of $7.0677 per share under a pre-established Rule 10b5-1 trading plan. After the sale, the reporting person beneficially owned 97,930 shares. The filing includes an offer to provide detailed breakdowns of the separate sale prices within the $7.03–$7.14 range and is signed by an attorney-in-fact on behalf of the reporting person.
908 Devices Inc. (MASS) Form 144 reports a proposed sale of 5,000 common shares to be executed through Morgan Stanley Smith Barney on the NASDAQ with an aggregate market value of $34,100. The filer acquired these shares on 03/22/2023 by previously exercised stock options from the issuer and paid in cash on that date. The filing shows 36,085,698 shares outstanding for the class and indicates no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
908 Devices insider Brandi C. Vann received equity awards on 08/01/2025. The filing reports 15,577 Restricted Stock Units (RSUs) and a stock option to buy 20,409 shares at $5.14. The RSUs convert one-for-one to common shares when vested and vest in substantially equal annual installments over three years, subject to continued service with prorated vesting on termination. The option shares vest in substantially equal monthly installments over 36 months beginning 08/01/2025. The Form 4 was filed late due to an inadvertent administrative error.
908 Devices Inc. (MASS) Form 3 records that Brandi C. Vann is reported as a director with an event date of 08/01/2025. The filing states no securities are beneficially owned and notes the form was filed late due to an inadvertent administrative error. The form is signed by an attorney-in-fact on 08/18/2025.
SSGA Funds Management, Inc. and State Street Corporation reported beneficial ownership of 908 Devices Inc. common stock. State Street disclosed 2,286,634 shares (6.4% of the class) and SSGA Funds Management disclosed 1,839,877 shares (5.1% of the class). Both reporting persons indicate no sole voting or dispositive power and instead report substantial shared voting and shared dispositive powers (State Street: 2,255,847 shared votes; SSGA: 1,834,577 shared votes). Filers certify these holdings were acquired in the ordinary course of business and not to change or influence control of the issuer.
Q2-25 continuing ops showed top-line growth but remained unprofitable. Revenue rose 14% YoY to $13.0 M, driven by handheld device sales (+13%) and recurring revenue (+28%). Gross profit improved 3% to $6.4 M, yet margin contracted to 48.9% (53.8% LY) as product cost inflation outpaced pricing. Operating expenses climbed 47% to $21.5 M, largely from a $6.8 M fair-value increase in RedWave acquisition earn-out; R&D grew 23% and SG&A eased 7%. As a result, loss from continuing ops widened to $12.9 M (-$7.6 M LY), or –$0.36 per share.
Strategic divestiture transformed the six-month picture. On 4 Mar 25, MASS sold its Desktop Portfolio to Repligen for $69.9 M cash, booking a $56.2 M pre-tax gain. Including this, H1-25 net income reached $30.3 M versus a $23.5 M loss LY; EPS swung to +$0.85. Cash & equivalents jumped to $61.8 M (43.4 M YE-24) and marketable securities to $56.8 M, lifting current assets to $147.9 M. Total liabilities fell slightly to $42.9 M, though a new $11.6 M current liability reflects contingent consideration. Operating cash burn for H1 was $20.8 M, covered by divestiture proceeds; capex remained modest at $0.3 M. Shares outstanding were 36.06 M at 30 Jun 25. A June-25 master supply agreement secures $6.6 M in committed orders over three years, with a $0.75 M upfront payment received in July.